Clinical trials: Endocrine System Disorder
Pain
Efficacy and Safety Study of Ataciguat Versus Placebo in Patients With Neuropathic Pain
The primary objective of this study is to assess the efficacy of ataciguat versus placebo in reducing pain intensity in patients with neuropathic pain.
- Trial name
- SERENEATI (NCT00799656)
- Testing
- ataciguat (HMR1766)
- Where
- 3 sites in Austria, Czechia and 1 more
- Volunteers
- 62 people
- Sponsor
- Sanofi
Diabetes Mellitus
EtCO2 for Monitoring and Predicting Severity of DKA in Pediatric Emergency, Doha, Qatar.
Metabolic acidosis is one of the important and life-threatening pathophysiological changes in DKA and its monitoring is essential.
- Trial name
- NCT04121572
- Testing
- Nasal cannula capnography
- Where
- Qatar
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Hamad Medical Corporation
Parathyroid Carcinoma, Hypercalcemia
An Intra-individual Titration Study of KRN1493 for the Treatment of Hypercalcemia in Patients With Parathyroid Carcinoma or Intractable Primary Hyperparathyroidism
This is an intra-individual titration study of KRN1493 to evaluate the safety and efficacy of KRN1493 for the treatment of hypercalcemia in patients with parathyroid carcinoma or intractable primary hyperparathyroidism (PHPT).
- Conditions
- Parathyroid Carcinoma, Hypercalcemia, Primary Hyperparathyroidism
- Trial name
- NCT01460030
- Testing
- Cinacalcet HCl
- Where
- Japan
- Sponsor
- Kyowa Kirin Co., Ltd.
Diabetes, Diabetes Mellitus, Type 1
Effect of NN5401 in Japanese Subjects With Type 1 Diabetes
This trial is conducted in Japan. The aim of this clinical trial is to investigate the blood sugar lowering effect of NN5401 (insulin degludec/insulin aspart (IDegAsp)) in Japanese subjects with type 1 diabetes.
- Trial name
- NCT01051102
- Testing
- insulin degludec/insulin aspart, biphasic insulin aspart 30
- Where
- Japan
- Volunteers
- 21 people
- Sponsor
- Novo Nordisk A/S
Congenital Adrenal Hyperplasia
A Study to Determine Eligibility for CAH-301 (A Study of Gene Therapy for Classic Congenital Adrenal Hyperplasia (CAH) [NCT04783181])
This pre-screening study is designed to determine potential eligibility of adults with classic CAH due to 21-hydroxylase deficiency (21-OHD) for participation in the CAH-301 [NCT04783181] gene therapy trial with BBP-631.
- Trial name
- NCT05101902
- Testing
- Pre-Screening
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Adrenas Therapeutics Inc
Type 2 Diabetes Mellitus
A Phase 3 Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With Type 2 Diabetes Mellitus.
ORA-013-3 is a randomized, controlled study to test the efficacy and safety of an oral capsule of ORMD-0801 at several doses in patients with Type 2 Diabetes Mellitus (T2DM) who have not responded well to other glucose-lowering…
- Trial name
- NCT06731075
- Testing
- ORMD-0801 8 mg, ORMD-0801 16 mg
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Oramed, Ltd.
Diabetes Mellitus, Type 2
Empagliflozin (BI 10773) in Type Two Diabetes (T2D) Patients, Open Label Extension
The objective of the current study is to investigate the safety and efficacy of BI 10773 in 2 different doses compared to Metformin or to Sitagliptin given for 78 weeks in different modalities of treatment in patients with type 2…
- Trial name
- NCT00881530
- Testing
- BI 10773, Metformin, Sitagliptin
- Where
- 137 sites in United States, Austria and 19 more
- Volunteers
- 660 people
- Sponsor
- Boehringer Ingelheim
Advanced Malignant Neoplasm, Breast Cancer
A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
ATLAS-101 is a Phase I/II clinical trial of AMXI-5001 in adult participants with advanced malignancies who have previously failed other therapies. The study has two phases.
- Conditions
- Advanced Malignant Neoplasm, Breast Cancer, Ovarian Cancer, Homologous Recombination Deficiency
- Trial name
- NCT04503265
- Testing
- AMXI-5001:Dose Escalation Phase I, AMXI-5001:Dose Expansion Phase II
- Where
- 4 sites in United States
- Volunteers
- 122 people
- Sponsor
- AtlasMedx, Incorporated
Diabetic Retinopathy
Evaluation of RC28-E Injection in Diabetic Retinopathy
This is a randomized, open-label, multicenter study of the efficacy and safety of RC28-E injection (a chimric decoy receptor trap fusion protein by dual blockage of VEGF and FGF-2) in the treatment of patients with moderately…
- Trial name
- NCT04782128
- Testing
- RC28-E injection
- Where
- China
- Volunteers
- 120 people
- Sponsor
- RemeGen Co., Ltd.
Chronic Kidney Disease, Type 2 Diabetes
A Study of RTA 402 in Chronic Kidney Disease (CKD) Patients With Type 2 Diabetes Mellitus
A Phase 2 study of RTA 402 in Chronic kidney disease (CKD) patients with type 2 diabetes mellitus.
- Trial name
- NCT01574365
- Testing
- RTA 402
- Where
- Japan
- Volunteers
- 53 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Germline BRCA1/2 Mutations and, Metastatic Adenocarcinoma of the Pancreas
Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy
A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Maintenance Olaparib Monotherapy in Patients with gBRCA Mutated Metastatic Pancreatic Cancer whose Disease Has Not Progressed on First Line Platinum…
- Trial name
- POLO (NCT02184195)
- Testing
- Olaparib
- Where
- 103 sites in United States, Australia and 10 more
- Volunteers
- 154 people
- Sponsor
- AstraZeneca
Fallopian Tube Cancer, Ovarian Cancer
Compare Fallopian Tube Cells Collected by Cytuity With Removed Ovarian/Tubal Tissue to Determine Presence of Malignancy
Prospective, multi-center, non-randomized study to assess the ability of the Cytuity device to collect cell samples from the fallopian tube that can be evaluated for the presence or absence of malignancy.
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Ovarian Neoplasms, Ovary Cancer
- Trial name
- nCYT (NCT03593681)
- Testing
- Hysteroscopic cell sampling of the fallopian tube
- Where
- 10 sites in United States
- Volunteers
- 150 people
- Sponsor
- Boston Scientific Corporation
Growth Hormone Disorder, Adult Growth Hormone Deficiency
First Human Dose Trial of NNC0195-0092 (Somapacitan) in Healthy Subjects
This trial is conducted in Europe. The aim of this trial is to assess safety, tolerability, pharmacokinetics (the exposure of the trial drug in the body) and pharmacodynamics (the effect of the investigated drug on the body) of…
- Conditions
- Growth Hormone Disorder, Adult Growth Hormone Deficiency, Growth Hormone Deficiency in Children, Healthy
- Trial name
- NCT01514500
- Testing
- somapacitan
- Where
- Germany
- Volunteers
- 105 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
Efficacy and Safety of Insulin Degludec/Insulin Aspart in Insulin-naïve Subjects With Type 2 Diabetes Using Two Dosing Regimens
This trial is conducted in Asia and North America. The aim of this trial is to compare the efficacy and safety of insulin degludec/insulin aspart (IDegAsp) once daily in insulin-naïve subjects with type 2 diabetes mellitus when…
- Trial name
- BOOST™ (NCT01365507)
- Testing
- insulin degludec/insulin aspart
- Where
- 42 sites in United States, Malaysia and 5 more
- Volunteers
- 276 people
- Sponsor
- Novo Nordisk A/S
Hypogonadism
A Study in Men With Low Testosterone to Measure the Effects of Testosterone Solution on Testosterone Levels, Sex Drive and Energy
The main purpose of this study is to evaluate if testosterone solution can raise testosterone hormone levels into the normal range, and also improve levels of sexual arousal, interest and drive and/or energy level, in men with…
- Trial name
- NCT01816295
- Testing
- Testosterone Solution
- Where
- 85 sites in United States, Argentina and 7 more
- Volunteers
- 715 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Non-Insulin-Dependent
An Evaluation of an Oral Antidiabetic Agent for the Treatment of Type 2 Diabetes
The purpose of this study is to determine if an investigational drug is safe and efficacious for poorly controlled type 2 diabetes mellitus.
- Trial name
- NCT00065312
- Testing
- naveglitazar
- Where
- 42 sites in United States
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus
Safety Study of TAK-559 in Treating Subjects With Type 2 Diabetes Mellitus
The purpose of this study was to determine the long-term safety of TAK-559, once daily (QD), in subjects with Type 2 Diabetes.
- Trial name
- NCT00762112
- Testing
- TAK-559
- Volunteers
- 316 people
- Sponsor
- Takeda
Solid Tumor, Ewing Sarcoma
Expanded Access of Vigil in Solid Tumors
This is an expanded access study involving an investigational product named Vigil. Vigil is considered immunotherapy. Patients who participated in another clinical trial sponsored by Gradalis, and had Vigil made from their tumor…
- Conditions
- Solid Tumor, Ewing Sarcoma, Ewing's Tumor Metastatic, Ewing's Sarcoma Metastatic
- Trial name
- NCT03842865
- Testing
- Vigil
- Where
- United States
- Sponsor
- Gradalis, Inc.
Obesity and Type 2 Diabetes
BMS-646256 in Obese and Overweight Type 2 Diabetics
This is a placebo-controlled, randomized, double-blind, parallel arm, multicenter, dose-ranging phase IIb trial to assess glycemic and weight loss efficacy and safety of BMS-646256 in overweight and obese patients with type 2…
- Trial name
- NCT00541567
- Testing
- ibipinabant
- Volunteers
- 600 people
- Sponsor
- Solvay Pharmaceuticals
Diabetic Foot Ulcer
NOX1416 in Treatment of Chronic Non-Healing Diabetic Foot Ulcers (NTCDU)
The goal of this multi-center,randomized, placebo controlled, evaluator-blinded study is to assess the efficacy and safety of NOX1416 in the treatment of chronic, non-healing, diabetic foot ulcers (DFUs).
- Trial name
- NTCDU (NCT06020664)
- Testing
- NOX-1416+SOC
- Where
- 6 sites in Israel
- Volunteers
- 30 people
- Sponsor
- NOxy Health Products, LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.